Get the Stockscreener App
22.70
25.89%
-7.93
After Hours:
22.60
-0.10
-0.44%
Vera Therapeutics Inc stock is traded at $22.70, with a volume of 12.05M.
It is down -25.89% in the last 24 hours and up +3.13% over the past month.
Vera Therapeutics Inc is a clinical stage biotechnology company. It is focused on developing and commercializing transformative treatments for patients with serious immunological diseases. The company's product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B lymphocyte stimulator and a proliferation-inducing ligand, which stimulate B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases.
See More
Previous Close:
$30.63
Open:
$21.265
24h Volume:
12.05M
Relative Volume:
8.18
Market Cap:
$1.21B
Revenue:
-
Net Income/Loss:
$-107.85M
P/E Ratio:
-10.27
EPS:
-2.21
Net Cash Flow:
$-106.82M
1W Performance:
+19.79%
1M Performance:
+3.13%
6M Performance:
-53.16%
1Y Performance:
-40.29%
1-Day Range:
$20.50
$23.14
1-Week Range:
$20.50
$33.00
52-Week Range:
$18.53
$51.61
Vera Therapeutics Inc Stock (VERA) Company Profile
Name
Vera Therapeutics Inc
Sector
Industry
Phone
650-770-0077
Address
2000 SIERRA POINT PARKWAY, SUITE 1200, BRISBANE
Compare VERA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
VERA
Vera Therapeutics Inc
|
22.70 | 1.21B | 0 | -107.85M | -106.82M | -2.21 |
|
VRTX
Vertex Pharmaceuticals Inc
|
450.50 | 113.52B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
493.22 | 52.93B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
300.83 | 39.71B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
585.93 | 35.00B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
255.86 | 26.57B | 3.81B | -644.79M | -669.77M | -6.24 |
Vera Therapeutics Inc Stock (VERA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-05-25 | Resumed | H.C. Wainwright | Buy |
| Feb-04-25 | Initiated | Wolfe Research | Outperform |
| Jan-28-25 | Initiated | Goldman | Buy |
| Nov-21-24 | Initiated | Wells Fargo | Overweight |
| Oct-16-24 | Initiated | Scotiabank | Sector Outperform |
| Jan-25-24 | Initiated | Oppenheimer | Outperform |
| Jan-08-24 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-18-23 | Initiated | Raymond James | Outperform |
| Nov-10-23 | Upgrade | Jefferies | Hold → Buy |
| Aug-16-23 | Initiated | Guggenheim | Buy |
| Jan-04-23 | Downgrade | Jefferies | Buy → Hold |
| Jan-04-23 | Downgrade | Wedbush | Outperform → Neutral |
| Jul-12-22 | Initiated | JP Morgan | Overweight |
| May-02-22 | Initiated | H.C. Wainwright | Buy |
| Apr-19-22 | Initiated | Wedbush | Outperform |
View All
Vera Therapeutics Inc Stock (VERA) Latest News
Otsuka’s IgAN Data Top Some Vera Results, But To What End? - insights.citeline.com
Vera Therapeutics (VERA) Stock Plummets Over 29% in Major Sell-Off - Daily Chhattisgarh News
Biotech Stock Vera Is Slumping After Monster Gain - Barron's
Vera Therapeutics stock sinks following competitor’s successful trial - Investing.com Australia
Vera Therapeutics stock sinks following competitor’s successful trial By Investing.com - Investing.com Canada
Vera stock drops as Otsuka bests with IgAN drug (VERA:NASDAQ) - Seeking Alpha
Finance Watch: Vera Raises Debt, Taysha And Trevi Price Offering After Big Trial Wins - insights.citeline.com
Scotiabank Increases the Price Target for Vera Therapeutics by $10 - MSN
FY2025 EPS Forecast for Vera Therapeutics Reduced by Analyst - Defense World
(VERA) Trading Advice - news.stocktradersdaily.com
Vera Therapeutics to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference - GlobeNewswire
Vera Therapeutics Enters $500M Credit Facility As It Nears FDA Filing For Kidney Disease Drug: Retail Sees Stock Touching $40 - MSN
Clinical-Stage Biotech Vera Therapeutics Joins Elite Goldman Sachs Healthcare Conference Lineup - Stock Titan
Latham & Watkins Advises Vera Therapeutics in US$500 Million Credit Facility With Oxford Finance - Latham & Watkins LLP
Vera Therapeutics Atacicept: Promising Step In IgAN, But Crowded Road Ahead (Rating Downgrade) - Seeking Alpha
Vera Therapeutics Announces Refinancing of Existing Oxford Debt Facility, Providing up to $500 Million of Term Loans - GlobeNewswire
Equities Analysts Set Expectations for VERA Q2 Earnings - Defense World
Vera Therapeutics (NASDAQ:VERA) Sees Large Volume Increase on Analyst Upgrade - Defense World
Vera Therapeutics eyes half billion dollars after kidney drug study - The Business Journals
Vera Therapeutics Enters $500M Credit Facility As It Nears FDA Filing For Kidney Disease Drug: Retail Sees Stock Touching $40 By Stocktwits - Investing.com India
Vera Therapeutics (VERA) Secures $500 Million Credit Facility - GuruFocus
Vera Therapeutics (VERA) Sees Price Target Boost Following Positive Trial Results | VERA Stock News - GuruFocus
Vera Therapeutics Secures $500M Loan Agreement - TipRanks
Vera Therapeutics Announces Refinancing of Existing Oxford Debt Facility, Providing up to $500 ... - Bluefield Daily Telegraph
Vera Therapeutics Lands Massive $500M Financing Deal as FDA Filing for Kidney Drug Approaches - Stock Titan
Two Sigma Investments LP Sells 7,102 Shares of Vera Therapeutics, Inc. (NASDAQ:VERA) - Defense World
Vera Therapeutics (NASDAQ:VERA) Price Target Raised to $65.00 at Scotiabank - Defense World
Vera Therapeutics (NASDAQ:VERA) Given New $85.00 Price Target at HC Wainwright - Defense World
Why Vera Therapeutics, Inc. (VERA) Skyrocketed On Monday - Yahoo Finance
These 10 Stocks Blew Past Expectations - Insider Monkey
Vera Therapeutics (NASDAQ:VERA) Shares Gap Up After Analyst Upgrade - Defense World
Vera Therapeutics: Primary endpoint was met in ORIGIN Phase 3 trial of atacicept - TipRanks
H.C. Wainwright ups Vera Therapeutics target on ‘home run’ data - TipRanks
Buy Rating for Vera Therapeutics: Promising Potential of Atacicept in IgA Nephropathy Treatment - TipRanks
Arthur He CFA Upgrades Vera Therapeutics on Promising Phase 3 Results for Atacicept in IgAN Treatment - TipRanks
Vera’s Atacicept Sets A New Efficacy Bar With Phase III Results In IgAN - insights.citeline.com
Vera Therapeutics (VERA) Surges 67.49% After Landmark Phase 3 Trial Results - Wealth Daily
Evercore ISI maintains outperform rating on Vera Therapeutics stock By Investing.com - Investing.com South Africa
Scotiabank Maintains Sector Outperform Rating for Vera Therapeutics (VERA) | VERA Stock News - GuruFocus
Vera rises after success in late-stage trial for IgA nephropathy treatment - Seeking Alpha
Nasdaq Edges Higher; ISM Manufacturing PMI Falls In May - Benzinga
Wedbush Raises Price Target on Vera Therapeutics to $32 From $26, Maintains Neutral Rating - marketscreener.com
Vera Therapeutics, Applied Digital, Kymera Therapeutics And Other Big Stocks Moving Higher On Monday - Benzinga
Vera Therapeutics, Inc. Announces Atacicept Achieves 46% Proteinuria Reduction in ORIGIN Phase 3 Trial in Adults with IgA Nephropathy - marketscreener.com
Vera Therapeutics Reports Positive Phase 3 Results for Atacicept in IgA Nephropathy Treatment - geneonline.com
Scotiabank Increases Vera Therapeutics (VERA) Price Target to $65 | VERA Stock News - GuruFocus
Scotiabank Adjusts Price Target on Vera Therapeutics to $65 From $55, Maintains Outperform Rating - marketscreener.com
Vera Therapeutics Says Trial of Kidney Disease Drug Achieves Primary Endpoint; Shares Jump - marketscreener.com
JPMorgan reiterates Vera Therapeutics stock rating after study data By Investing.com - Investing.com South Africa
TD Cowen maintains buy rating for Vera Therapeutics stock - Investing.com
JPMorgan reiterates Vera Therapeutics stock rating after study data - Investing.com
Vera Therapeutics Inc Stock (VERA) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.21%
1.51%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):